Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

CD33 Inhibitor - 2019 Pipeline Insight Report Featuring Affimed Therapeutics, Boehringer Ingelheim, PersonGen Biomedicine & ImmunoGen - ResearchAndMarkets.com

November 4, 2019

DUBLIN--(BUSINESS WIRE)--Nov 4, 2019--

The “CD 33 Inhibitor -Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

CD 33 Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CD 33 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Descriptive coverage of pipeline development activities for CD 33 Inhibitor

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for CD 33 Inhibitor

The report assesses the active CD 33 Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the Report

Reasons to Buy

Companies Mentioned

Key Topics Covered

1. Report Introduction

2. CD 33 Inhibitor - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. CD 33 Inhibitor Pipeline Products in Clinical Stages

6. CD 33 Inhibitor Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/okryc7

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005836/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/04/2019 01:59 PM/DISC: 11/04/2019 01:59 PM